Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $13.75 USD
Change Today -0.08 / -0.58%
Volume 10.0K
MCUR On Other Exchanges
Symbol
Exchange
NASDAQ GM
As of 8:10 PM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

macrocure ltd (MCUR) Snapshot

Open
$13.85
Previous Close
$13.83
Day High
$13.95
Day Low
$13.52
52 Week High
06/22/15 - $16.10
52 Week Low
10/1/14 - $6.82
Market Cap
222.4M
Average Volume 10 Days
26.9K
EPS TTM
$-2.09
Shares Outstanding
16.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MACROCURE LTD (MCUR)

macrocure ltd (MCUR) Related Businessweek News

No Related Businessweek News Found

macrocure ltd (MCUR) Details

Macrocure Ltd., a biotechnology company, focuses on developing, manufacturing, and commercializing novel cell therapy products for the treatment of chronic and other hard-to-heal wounds in Israel. Its lead cell-based biological product includes CureXcell, which is in two Phase III clinical trials for the treatment of hard-to-heal diabetic foot ulcers and hard-to-heal venous leg ulcers. Macrocure Ltd. was founded in 2008 and is headquartered in Petach Tikva, Israel.

28 Employees
Last Reported Date: 03/18/15
Founded in 2008

macrocure ltd (MCUR) Top Compensated Officers

President and Chief Executive Officer
Total Annual Compensation: $1.2M
Chief Medical Officer
Total Annual Compensation: $375.0K
Vice President of Finance and Israeli Site Ma...
Total Annual Compensation: $219.2K
Compensation as of Fiscal Year 2014.

macrocure ltd (MCUR) Key Developments

Macrocure Ltd. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 10:30 AM

Macrocure Ltd. Presents at Jefferies 2015 Global Healthcare Conference, Jun-04-2015 10:30 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Nissim Mashiach, President and Chief Executive Officer.

Macrocure Ltd. Reports Consolidated Unaudited Earnings Results for the First Quarter Ended March 31, 2015; Reaffirms Earnings Guidance for 2015

Macrocure Ltd. reported consolidated unaudited earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported operating loss of $6,863,000 compared with $3,352,000 for the same period last year. Loss before income tax was $6,855,000 compared with $3,357,000 for the same period last year. Loss for the period was $6,903,000 or $0.38 basic and diluted per share compared with $3,397,000 or $0.46 basic and diluted per share for the same period last year. Net cash used in operating activities was $5,642,000 compared with $2,937,000 for the same period last year. Purchase of property and equipment was $5,000 compared with $75,000 for the same period last year. The company reiterates that expected cash used for its ongoing operating activities in 2015 will be $21 million to $25 million, reflecting anticipated expenditures to complete its current Phase III clinical trials in process in 2015. As previously disclosed, that range excludes approximately $4 million in potential capital expenditures in 2015 primarily related to the company's new U.S. manufacturing facility.

Macrocure Ltd. Appoints Lewis Gryziewicz as Vice President, Regulatory Affairs

Macrocure Ltd. announced that Lewis Gryziewicz has joined company as Vice President, Regulatory Affairs, effective May 1, 2015. Dr. Gryziewicz held senior-level positions within Regulatory Affairs, most recently as Global Regulatory Liaison for Ophthalmology, where he was responsible for the submission and approval of global marketing applications, liaising with global regulatory agencies, and regulatory strategy, which led to product approvals, including U.S. and European Union approvals of Ozurdex and Combigan and approval in the U.S. and Japan for Alphagan P and Lumigan, among others.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MCUR:US $13.75 USD -0.08

MCUR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MCUR.
View Industry Companies
 

Industry Analysis

MCUR

Industry Average

Valuation MCUR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MACROCURE LTD, please visit www.macrocure.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.